Name: Xilio Therapeutics, Inc. (XLO) Financial Statements
Creator: FinSpry

Xilio Therapeutics Income Statement Analysis

Revenue, earnings, and profit margins in millions USD

Scale:

Scroll to see more

Xilio Therapeutics, Inc. income statement - Annual data in millions USD
Breakdown	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Revenue & Gross Profit
Revenue	6.34	0.00	0.00	0.00	0.00
Cost of Revenue	0.00	0.00	0.00	0.00	0.00
Gross Profit	6.34	0.00	0.00	0.00	0.00
Operating Expenses
Research & Development	41.21	52.14	59.20	51.19	43.91
Selling, General & Administrative	24.78	27.00	29.95	23.86	10.65
Operating Expenses	66.93	79.13	89.15	75.04	54.56
Operating Income	-60.58	-79.13	-89.15	-75.04	-54.56
Other Income/Expense
Interest Income	0.00	0.00	0.00	0.00	0.00
Interest Expense	0.10	-0.70	-0.80	-0.60	-0.60
Other Income/Expense	2.34	3.43	0.93	-0.76	-0.06
Income
Income Before Tax	-58.24	-76.40	-88.22	-75.80	-55.22
Income Tax Expense	0.00	0.00	0.00	0.00	0.00
Net Income	-58.24	-76.40	-88.22	-75.80	-55.22
Net Income - Continuous Operations	-58.24	-76.40	-88.22	-75.80	0.00
Net Income - Discontinued Operations	0.00	0.00	0.00	0.00	0.00
EBITDA	-58.00	-77.23	-87.30	-73.55	-53.50
EBIT	-58.20	-79.13	-89.15	-75.04	-54.56
Depreciation & Amortization	1.64	1.90	1.85	1.50	1.07
Earnings Per Share
Basic EPS	-1.00	-3.00	-3.00	-14.00	-105.00
Diluted EPS	-1.00	-3.00	-3.00	-14.00	-105.00
Basic Shares Outstanding	53.51	27.50	27.39	5.61	0.52
Diluted Shares Outstanding	53.51	27.50	27.39	5.61	0.52